somatotroph raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-07. Anything still debated is marked as such rather than presented as settled.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Beaumont said that with the exception of the Kreis Stuhm, where Poles admittedly numbered 15,500 out of a population of 36,500 (42%), they had Polish sympathies since they were Catholics. In the other districts, with the exception of Allenstein, Poles depicting themselves as Mazurians were Lutherans and German in a national conviction. On the eve of the plebiscite, Beaumont reported that Poles strictly guarded the new frontier between East Prussia and Poland to prevent people from passing to East Prussia without vexatious formalities. They held up trains for hours and constantly interrupted or even completely suppressed postal, telegraphic and telephonic communication service. The great bridge over the Vistula at Dirschau was barred by sentries in French uniforms, "who refuse to understand any language but Polish". As a result, Beaumont wrote that area to have been "cut off from its shopping centre and chief port almost completely". After the plebiscite, the bridge was removed. To Beaumont, it would be "desirable to convey a hint to the Warsaw Government that their present policy is scarcely calculated to gain them votes". Sir Horace Rumbold, the British minister in Warsaw, also wrote to George Curzon on 5 March 1920 that the Plebiscite Commissions at Allenstein and Marienwerder "felt that they were isolated both from Poland and from Germany" and that the Polish authorities were holding up supplies of coal and petrol to those districts.
=== Educational goals === John White (2013) investigated the educational goals at public schools in Britain. School-education involves both cognitive and conceptual learning, but also the development social skills and personal development. Ideally, children develop self-confidence, and create purpose for themselves. According to White, in the past schools only focused on knowledge and education but now Britain has moved to a broader direction. White's Every Child Matters initiative seeks to enhance children's well-being across the range of children's services.
As mayor, Bukele began a "reordering" ("reordenamiento") to revitalize the city's historic downtown area and combat crime. On the day Bukele took office, he reverted the names of two streets in San Salvador (Calle Mayor Roberto D'Aubuisson and Boulevard Coronel José Arturo Castellanos) to Calle San Antonio Abad and Boulevard Venezuela, respectively. Both names had been changed by Bukele's predecessor, Norman Quijano. Zamora, who had become a member of San Salvador's municipal council, stated that the names were reverted due to flaws in the initial renaming process. He added that another street would be named in honor of Castellanos, who provided fake Salvadoran passports to 40,000 Central European Jews to help them escape the Holocaust. Bukele renamed 89 Avenida Norte in honor of Castellanos in June 2016. In December 2016, Bukele inaugurated the Cuscatlán Market to encourage street vendors to relocate their businesses. Many vendors refused to move, despite the market. Political opponents and investigative journalists accused him of negotiating with gangs to organize its construction, since it was located in gang-controlled territory. In January 2016, Bukele began a "San Salvador 100% Illuminated" campaign to "have a light on every corner of San Salvador" to combat crime in the city. The campaign was completed by May 2016. He also installed video-surveillance cameras in parts of San Salvador that were severely affected by crime. Bukele inaugurated the renovated downtown Gerardo Barrios Plaza in October 2017, and the new downtown Lineal Plaza in April 2018.
Sources: en.wikipedia.org
In December 2024, the Auditor General of Ontario questioned the financial prudence of the relocation. Contrary to the Ford government's business plan analysis, which projected $257 million in savings over 50 years, the AG found that relocation costs have already exceeded the anticipated savings, reaching approximately $400 million.In May 2025, the Canadian Architect magazine reported that draft versions of the structural engineering report by Rimkus Consulting that the Ontario government had relied on in deciding to close the centre, had originally recommended routine repairs and not closure, up until May 2024. This revelation was added to earlier reporting from Global News that Infrastructure Ontario had been in frequent communication with Rimkus in the leadup to the public release of the report in June 2024, and led the magazine to conclude that the language describing the consequences of not doing the routine repair that was later used to justify the closure had been inserted after political pressure. In February 2026, Ford unveiled the designs of the new building and announced that a contract had been awarded for its construction. It will cost an estimated $1 billion and will be smaller than the original facility, with a footprint of about 400,000 square feet. The Centre would also incorporate the Ontario Place pods as exhibit space and the Cinesphere. The proposed move has been controversial.
==== Basic Laboratory Cancer Centers ==== Basic Laboratory Cancer Centers conduct only laboratory research and do not provide patient treatment. Basic Laboratory Cancer Centers are more often affiliated with research institutes rather than universities. They are eligible to apply for up to $1.2 million per year.
=== Pharmacokinetics === In the in vitro studies, eluxadoline was found to be transported by OAT3 (SLC22A8), OATP1B1 (SLCO1B1), and BSEP (ABCB11) at the highest concentrations tested (400 ng/ml, which is 162-fold larger than the observed Cmax of the highest therapeutic dose of 100 mg). However, it was not to be transported by OCT1 POU2F1, OAT1 (organic anion transporter 1), OCT2, OATP1B3 (SLCO1B3), P-gp (P-glycoprotein), or BCRP (ABCG2). Multidrug resistance-associated protein 2 (MRP2)-vesicular accumulation of eluxadoline was observed, indicating that the drug is a substrate of MRP2. Eluxadoline was not found to inhibit BCRP-, BSEP-, MRP2-, OCT1-, OCT2-, OAT1-, OAT3-, or OATP1B3-mediated transport of probe substrates but inhibited the transport of probe substrates of OATP1B1 and P-gp. In the in vitro studies, it was observed that eluxadoline is an in vivo substrate of OATP1B1, OAT3, and MRP2. Finally, no inhibition or induction of cytochrome P450 enzymes was observed. Following a 100 mg dose of eluxadoline, the Cmax was about 2 to 4 ng/ml and AUC was 12 to 22 ng.h/ml. Eluxadoline has linear pharmacokinetics with no accumulation upon repeated twice daily dosing. Taking eluxadoline with high fat meal decreased the Cmax by 50% and AUC by 60%.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。